Abstract
This study was conducted to retrospectively investigate the efficacy and safety of pegaspargase, gemicitabine, oxaliplatin and dexamethasone (Peg-GemOD) combination chemotherapy as a first-line therapy for advanced-stage extranodal NK/T cell lymphoma (ENKTL). Eighteen patients with newly diagnosed stage III/IV ENKTL were subjected to 3-6 cycles of Peg-GemOD chemotherapy. After 3 cycles of therapy, the overall response rate was 67% (12/18) with a complete response rate of 28% (5/18) and a partial response rate of 39% (7/18). The median overall survival (OS) and progression-free survival (PFS) time were 10 and 8.5months respectively. For those responders, the median OS and PFS time were significantly better than those of non-responders (median OS, 15 vs. 10months; P=0.001 and median PFS, 15 vs. 7months; P=0.001). Furthermore, patients with low plasma EBV-DNA levels after induction chemotherapy had a remarkably longer OS and PFS time. The toxicity of Peg-GemOD regimen was acceptable.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
